|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.||Founder, Chairman & CEO||3,51M||5,08M||1955|
|Mr. Michael I. Benkowitz||Pres & COO||1,96M||17,34M||1972|
|Mr. James C. Edgemond||CFO & Treasurer||1,42M||N/D||1968|
|Mr. Paul A. Mahon J.D.||Exec. VP, Gen. Counsel & Corp. Sec.||1,67M||12,39M||1964|
|Mr. Dewey Steadman C.F.A.||Head of Investor Relations||N/D||N/D||N/D|
|Ms. Holly Hobson||Associate VP of HR||N/D||N/D||N/D|
|Kevin T. Gray||Sr. VP of Strategic Operations & Logistics||N/D||N/D||N/D|
|Mr. Patrick Poisson||Exec. VP of Technical Operations||N/D||N/D||1968|
|Mr. Gil Golden||Sr. VP & Chief Medical Officer||N/D||N/D||N/D|
|Dr. Leigh Peterson||VP of Product Devel.||N/D||N/D||N/D|
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
L'ISS Governance QualityScore di United Therapeutics Corporation al 1 settembre 2022 è 2. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 2.